Biologics Market Size, Share, Growth Analysis, By Product(Microbial, Antisense and RNAi Therapeutics Mammalian, Others), By Disease(Oncology, Hematology Disorders), By Manufacturing(Outsourced, and In-house), By Region - Industry Forecast 2024-2031

The global biologics market is characterized via extreme opposition amongst key market gamers striving to hold their market position and benefit from a competitive side. The marketplace is dominated with the resource of essential pharmaceutical agencies, biotechnology companies, and agreement production agencies (CMOs) specializing in biologic drug improvement and production. Companies which include Biogen, Genentech, and Gilead Sciences are interested in growing modern-day biologics and investing in studies to expand medical understanding and recuperation options. Biogen's more than one sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made vast contributions to their market presence.

Biologics Market Top Player’s Company Profiles

• Roche (Switzerland)

• Johnson & Johnson (US)

• AbbVie (US)

• Amgen (US)

• Novartis (Switzerland)

• Pfizer (US)

• Merck & Co. (US)

• AstraZeneca (UK)

• Bristol Myers Squibb (US)

• Sanofi (France)

• Eli Lilly and Company (US)

• Gilead Sciences (US)

• Biogen (US)

• Celgene (US)

• Novo Nordisk (Denmark)

• Takeda Pharmaceutical Company (Japan)

• Bayer (Germany)

• GlaxoSmithKline (UK)

• Boehringer Ingelheim (Germany)

• Vertex Pharmaceuticals (US)

Biologics Market